Quantcast

Latest Cisplatin Stories

2008-11-14 09:00:34

CALGARY, Nov. 14 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that a poster presentation authored by Dr. Anders Kolb of the Nemours Center for Childhood Cancer Research entitled "Systemic Administration of REOLYSIN Inhibits Growth of Human Sarcoma Xenografts Alone and in Combination with Cisplatin and Radiation" is scheduled to be presented today at the 14th Annual Meeting of the Connective Tissue Oncology Society (CTOS). The meeting is being...

2008-10-02 12:06:58

Alimta has received US approval for use as a first-line therapy in locally advanced and metastatic non-small cell lung cancer in combination with cisplatin. This third FDA approval for Alimta follows its prominent use in patients with non-squamous carcinoma cell histology and highlights the shift towards a more tailored approach for lung cancer therapy. Alimta (pemetrexed) received US approval as a first-line therapy for locally advanced and metastatic non-small cell lung cancer (NSCLC)...

2008-09-30 09:45:00

Eli Lilly and Company has received approval from the FDA for the use of Alimta in combination with cisplatin, in the first-line treatment of locally-advanced and metastatic non-small cell lung cancer, for patients with nonsquamous histology. This marks the third US indication for Alimta. In 2004, Alimta has received consecutive approvals: first in combination with cisplatin as a treatment for patients with malignant pleural mesothelioma, whose disease is unresectable or who are otherwise not...

2008-09-29 09:00:14

INDIANAPOLIS, Sept. 29 /PRNewswire-FirstCall/ -- Eli Lilly and Company announced today it received approval from the U.S. Food and Drug Administration (FDA) for the use of ALIMTA(R) (pemetrexed for injection), in combination with cisplatin, in the first-line treatment of locally-advanced and metastatic non-small cell lung cancer (NSCLC), for patients with nonsquamous histology. ALIMTA is not indicated for treatment of patients with squamous cell non-small cell lung cancer. NSCLC is the...

2008-08-29 00:00:36

U.S. researchers say they have linked a genetic variant of a protein to resistance to the chemotherapy drug cisplatin. The University of California, San Diego, researchers found that when a specific variant form of PMS2 -- a cell repair protein that fixes DNA mistakes and plays a role in cell death -- is active, cisplatin doesn't kill cancer cells the way it normally does. In experiments using mouse cells, the researchers, led by Jean Wang and Richard Kolodner, found PMS2 normally...

2008-08-07 18:01:53

SEATTLE, Aug. 7 /PRNewswire/ -- Sound Pharmaceuticals (SPI) has received FDA notification that it may proceed with its Phase II study to prevent chemotherapy induced hearing loss. The Ph-II study will enroll 80 patients with advanced head and neck, and non-small cell lung cancer at the National Center for Rehabilitative Auditory Research at the Veterans Administration Hospital and the Oregon Health and Science University in Portland, Oregon. Hearing loss due to ototoxic medications such...

2008-07-17 09:00:19

SAN ANTONIO, July 17 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. ("BioNumerik") today announced that patients with adenocarcinoma (the most frequently occurring form of lung cancer) participating in a Phase II clinical trial of Tavocept(TM) showed a survival increase of approximately 198 days (6.5 months). The trial observations included an approximate 40% reduction in mortality for adenocarcinoma patients receiving Tavocept. The percentage of adenocarcinoma patients in the Tavocept...

2008-06-24 02:30:28

U.S. medical scientists say they've found a compound that effectively treats colorectal cancer but with fewer side effects than with a commonly used drug. The newly investigated compound, known as cDPCP, is an analogue of cisplatin, a potent anticancer agent. The study found cDPCP might better target colorectal cells, potentially sparing other body tissues from damage, said Massachusetts Institute of Technology researchers. This compound, the antitumor properties of which were established...

2008-06-20 00:00:06

Canopus BioPharma: Len Rothstein, 818-980-5008 Fax. 818-980-5088 President len@canopusbiopharma.com or Investor Relations: Darrow Associates, Inc. Jordan Darrow, 631-367-1866 Fax. 631-614-3612 jdarrow@darrowir.com Canopus BioPharma, Inc. (OTC: CBIA), has confirmed the efficacy of its oncology candidate, CB1400, as a tumor reducing agent and has also demonstrated the synergistic effect of this drug in combination with both cisplatin and cetuximab (Erbitux) in two mice...

2008-06-19 09:00:09

LOS ANGELES, California, June 19 /PRNewswire-FirstCall/ -- Canopus BioPharma, Inc. , has confirmed the efficacy of its oncology candidate, CB1400, as a tumor reducing agent and has also demonstrated the synergistic effect of this drug in combination with both cisplatin and cetuximab (Erbitux) in two mice lung cancer models. Chairman of Canopus BioPharma, Dr. Patrick Prendergast, stated, "We at Canopus are encouraged with the discovery of this new use for CB1400 to increase efficacy and...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related